This clinical trial is focused on studying the effects of a treatment for patients who have experienced acute kidney injury (AKI) and are being discharged from the Intensive Care Unit (ICU). The treatment being tested involves the use of a medication called Irbesartan, which is an angiotensin receptor blocker. This type of medication is commonly used to manage high blood pressure and protect the kidneys. The study will compare the effects of Irbesartan with a placebo to understand its impact on patients’ health after they leave the ICU.

The purpose of the study is to evaluate how the treatment affects the heart and overall health of patients during the year following their discharge from the ICU. Participants in the study will receive either Irbesartan or a placebo, and their health will be monitored over the course of a year. The study aims to see if Irbesartan can help reduce the risk of major heart-related events, such as heart attacks or strokes, and improve kidney function in patients who have had AKI.

Throughout the study, researchers will track various health outcomes, including the occurrence of any new episodes of AKI, changes in kidney function, and any heart-related issues. The study will also collect biological samples at the beginning and end of the study to help understand the effects of the treatment. This research is important for finding better ways to support patients recovering from AKI and improve their long-term health outcomes.